Proto-Oncogene Proteins c-met, antagonists & inhibitors
- Name
- Proto-Oncogene Proteins c-met, antagonists & inhibitors
- Accession Number
- DBCAT001756
- Description
Not Available
- Drugs
Drug Drug Description Tivantinib Tivantinib has been investigated in Solid Tumors. Tepotinib An oral tyrosine kinase inhibitor targeted against MET for the treatment of metastatic non-small cell lung cancer in patients exhibiting MET exon 14 skipping mutations. - Drugs & Drug Targets
Drug Target Type Tivantinib Hepatocyte growth factor receptor target Tepotinib P-glycoprotein 1 transporter Tepotinib Cytochrome P450 3A4 enzyme Tepotinib Cytochrome P450 2C8 enzyme Tepotinib ATP-binding cassette sub-family G member 2 transporter Tepotinib Hepatocyte growth factor receptor target Tepotinib Nischarin target Tepotinib Melatonin receptor type 1B target Tepotinib Serum albumin carrier Tepotinib Alpha-1-acid glycoprotein 1 carrier Tepotinib Solute carrier family 22 member 1 transporter Tepotinib Solute carrier family 22 member 2 transporter Tepotinib Multidrug and toxin extrusion protein 1 transporter Tepotinib Multidrug and toxin extrusion protein 2 transporter Tepotinib Bile salt export pump transporter Tepotinib Cytochrome P450 2C9 enzyme